​​​​​​​​​South East London Area Prescribing Committee


This page is being updated until the content is moved to the SEL CCG website

The South East London Area Prescribing Committee (APC) was established in 2013 and is a partnership committee which discusses and makes recommendations on medicines issues.

Partner NHS organisations in South East London who are part of the APC are:

Bexley, Bromley, Greenwich, Lambeth, Lewisham and Southwark Clinical Commissioning Groups (CCGs),  Guys and St Thomas Foundation Trust, Kings College Hospital Foundation Trust,  South London and Maudsley Foundation Trust, Oxleas NHS Foundation Trust and Lewisham & Greenwich NHS Trust.

The committee also has representation from local Healthwatch organisations, NHS England London Area Team, and support from Medicines Information Services and the North East London Commissioning Support Unit.

Its aims are;

  • To provide a collective clinical leadership committee to ensure co-operation and consistency of approach to medicines optimisation across South East London
  • To enable all clinicians and commissioners to work together to ensure that patients have safe and consistent access to  medicines with the best outcomes
  • To advise on implementation of best practice around medicines, including National Institute for Health and Care Excellence ( NICE) guidelines and technology appraisals to encourage rapid and consistent implementation
  • To enable local NHS stakeholders and clinicians to exert a population approach to the prioritisation, improvement and quality of healthcare related to medicines.

The Medicines and Pathways Review Group is a working group of the APC which meets monthly to assess new medicines for prescribing within South East London, where these are intended to be prescribed in primary care or commissioned by Clinical Commissioning Groups.  Where primary care or commissioned medicines are subject to a new NICE technology appraisal, the APC will advise on best adoption and implementation in line with NICE. South East London wide treatment pathways and prescribing guidelines are also developed through the Committee and its sub-groups. 

The Local Trusts retain a Joint Formulary Committee which considers new drugs and changes of use of existing drugs which are used only within hospitals and are not subject to any specific commissioning arrangements.

If you are a South East London clinician and you wish to make an application for a new medicine to be considered by the APC please contact your local trust formulary pharmacist or, for primary care applications, your CCG medicines team.

Correspondence to the APC should be directed to:

T: 020 3049 4197

E: lamccg.medicinesoptimisation@nhs.net

ACUTE CORONARY SYNDROME Rivaroaxban prescribing guidance June 2016.pdf
ACUTE CORONARY SYNDROME Rivaroxaban Notification of Initiation June 2016.docx
ACUTE CORONARY SYNDROME Rivaroxaban Transfer of care June 2016.docx
ANTIPLATELETS Summary of Options in CV Disease August 2017.pdf
ATRIAL FIBRILLATION Apixaban guidelines June 2016.pdf
ATRIAL FIBRILLATION Dabigatran June 2016.pdf
ATRIAL FIBRILLATION DOAC Initiation June 2016.docx
ATRIAL FIBRILLATION DOAC Transfer of Care June 2016.docx
ATRIAL FIBRILLATION Edoxaban guidelines June 2016.pdf
ATRIAL FIBRILLATION Rivaroxaban guidance June 2016.pdf
Calculating renal function for DOACs Sept 2019 FINAL.pdf
CHRONIC STABLE ANGINA treatment guidance May 2017.pdf
DOAC FAQs Sept 2020 FINAL.pdf
DOAC initiation and monitoring template SEL SEPT 2020 FINAL.pdf
DOAC patient referral pathway NVAF March 2020.pdf
Enoxaparin prescribing in primary care June 2018.pdf
Heart Failure adult treatment GL SEL FINAL July 2020.pdf
HEART FAILURE Sacubitril valsartan Initiation FINAL July 2020.docx
HEART FAILURE Sacubitril valsartan Transfer of Prescri FINAL July 2020.docx
HYPERTENSION -  Hypertension guidance Oct 2014.pdf
HYPERTENSION - BP monitoring and management algorithm Oct 2014.pdf
HYPERTENSION - Traffic Light Guide to BP Measurment Oct 2014.pdf
Initiation of Anticoagulation in NVAF March 2020.pdf
LIPIDS Guidance for the Management of Hypertriglyceridaemia July 2018.pdf
LIPIDS Guidance on prescribing statins.pdf
LIPIDS Management for Prevention of CVD in Adults.pdf
PCSK9 Inhibitors in hypercholesterolaemia March 2017.pdf
POTS - IST Ivabradine prescribing guidance  Jan 2018.pdf
POTS - IST Ivabradine Transfer of prescribing responsibility Jan 2018.docx
POTS - IST Notification of Initiation of ivabradine  Jan 2018.docx
POTS - IST Notification of Initiation of midodrine  Jan 2018.docx
POTS- IST Midodrine Transfer of prescribing responsibility Jan 2018.docx
POTS-IST-OH Midodrine prescribing guidance  Jan 2018.pdf
SEL Oral Anticoagulant Alert Card (information for HCPs) Oct 16.pdf
Self Monitoring of INR Pan London Framework for Adult Patients.pdf
Self- monitoring patient information leaflet.pdf
VTE - anticoagulant choice guidance SEL Sept 2020 FINAL.pdf
VTE - DOAC Patient Referral pathway SEPT 2020 FINAL.pdf
VTE DOACS Apixaban prescribing guidance June 2016.pdf
VTE DOACS Dabigatran prescribing guidance June 2016.pdf
VTE DOACS Edoxaban prescribing guidance June 2016.pdf
VTE DOACS Notification of Initiation June 2016.docx
VTE DOACS Primary care treatment summary for VTE Management June 2016.pdf
VTE DOACS Rivaroxaban prescribing guidance June 2016.pdf
VTE DOACS Transfer of Care June 2016.docx